Niharika Samala1, Archita Desai1, Eduardo Vilar-Gomez1, Emily R Smith1, Samer Gawrieh1, Carla D Kettler2, Francis Pike2, Naga Chalasani3. 1. Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana. 2. Department of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana. 3. Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana. Electronic address: nchalasa@iu.edu.
Abstract
BACKGROUND & AIMS: We studied impaired quality of life (QOL) and its determinants among individuals with nonalcoholic fatty liver disease (NAFLD). METHODS: We collected data from 341 patients with NAFLD who completed the short form 36 (SF-36) questionnaire. Body composition and liver fibrosis were assessed in patients with NAFLD using bioelectrical impedance and transient elastography, respectively. Advanced fibrosis was defined as liver stiffness measurements (LSMs) of 12.1 kPa or greater. SF-36 scores of patients with NAFLD were compared with SF36 scores of individuals with chronic medical illnesses and the general population obtained from the published literature. RESULTS: Among patients with NAFLD, percent body fat was negatively associated with scores from all 8 SF-36 scales, whereas lean body mass was positively associated with scores from 5 of 8 SF-36 scales. On multivariable analysis, SF-36 PF scores were negatively associated with type 2 diabetes, body mass index, and LSM and positively associated with lean body mass and level of alanine aminotransferase. Patients with NAFLD, and even those without advanced fibrosis, had significantly lower mean QOL scores than the control group or the general population. CONCLUSIONS: Individuals with NAFLD, even those without advanced fibrosis, have lower QOL than controls. Body composition associates with QOL in patients with NAFLD; both of the modifiable factors independently associated with QOL are related to body composition. Further studies are needed to investigate if interventions to improve body composition can increase QOL for patients with NAFLD.
BACKGROUND & AIMS: We studied impaired quality of life (QOL) and its determinants among individuals with nonalcoholic fatty liver disease (NAFLD). METHODS: We collected data from 341 patients with NAFLD who completed the short form 36 (SF-36) questionnaire. Body composition and liver fibrosis were assessed in patients with NAFLD using bioelectrical impedance and transient elastography, respectively. Advanced fibrosis was defined as liver stiffness measurements (LSMs) of 12.1 kPa or greater. SF-36 scores of patients with NAFLD were compared with SF36 scores of individuals with chronic medical illnesses and the general population obtained from the published literature. RESULTS: Among patients with NAFLD, percent body fat was negatively associated with scores from all 8 SF-36 scales, whereas lean body mass was positively associated with scores from 5 of 8 SF-36 scales. On multivariable analysis, SF-36 PF scores were negatively associated with type 2 diabetes, body mass index, and LSM and positively associated with lean body mass and level of alanine aminotransferase. Patients with NAFLD, and even those without advanced fibrosis, had significantly lower mean QOL scores than the control group or the general population. CONCLUSIONS: Individuals with NAFLD, even those without advanced fibrosis, have lower QOL than controls. Body composition associates with QOL in patients with NAFLD; both of the modifiable factors independently associated with QOL are related to body composition. Further studies are needed to investigate if interventions to improve body composition can increase QOL for patients with NAFLD.
Authors: Maurice Michel; Alisha Wahl; Malena Anders; Saleh A Alqahtani; Wolfgang M Kremer; Peter R Galle; Christian Labenz; Daniel Grimm; Martin Sprinzl; Jörn M Schattenberg Journal: Qual Life Res Date: 2022-08-22 Impact factor: 3.440
Authors: Diego Martínez-Urbistondo; RodrigoSan San Cristóbal; Paula Villares; Miguel Ángel Martínez-González; Nancy Babio; Dolores Corella; José Luis Del Val; José M Ordovás; Ángel M Alonso-Gómez; Julia Wärnberg; Jesús Vioque; Dora Romaguera; José López-Miranda; Ramon Estruch; Francisco J Tinahones; José Lapetra; J Luís Serra-Majem; Aurora Bueno-Cavanillas; Josep A Tur; Alba Marcos; Xavier Pintó; Miguel Delgado-Rodríguez; Pilar Matía-Martín; Josep Vidal; Clotilde Vázquez; Emilio Ros; María Vanessa Bullón Vela; Antoni Palau; Marta Masagué; Itziar Abete; Anai Moreno-Rodríguez; Inma Candela-García; Jadwiga Konieczna; Antonio García-Ríos; Oscar Lecea Juárez; Paco Martín; Albert Goday; M Ángeles Zulet; Jessica Vaquero-Luna; María Del Carmen Sayón Orea; Isabel Megías; Enric Baltasar; J Alfredo Martínez; Lidia Daimiel Journal: Front Endocrinol (Lausanne) Date: 2022-06-29 Impact factor: 6.055